Omeros Corporation - OMER - Financial Statement Analysis

All financial statement analysis reports for your requested company can be accessed below. The SIC # column is the SIC Code for the industry under which the current company is analyzed. When a report is purchased the SIC Code indicated is the industry that the company displayed will be compared against. If a different industry is desired for comparison, purchase of a separate industry analysis is suggested.

In addition to the ratio analysis reports, the latest business news headlines involving your company or industry sector are hyperlinked for your convenience along with the stock ticker for the company displayed.

Financial statement analysis updated: June 16, 2013

Omeros Corporation - SIC # 2834

Ticker	Exchange	SIC #	Website	Latest Ticker
OMER	Nasdaq	2834	http://www.omeros.com/	4.97 +0.01
Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company: Publicly Traded Company Industry Ratios Publicly Traded Company VS. Industry Ratios Publicly Traded Company VS Publicly Traded Company Private Company VS Publicly Traded Company
Latest Headlines for Omeros Corporation Nasdaq stocks posting largest percentage decreases - Jun 17th, 2013 4:05 pm Omeros Obtains Regulatory Approval to Initiate Phase 1 Clinical Trial for Lead Antibody in MASP-2 Program - Jun 13th, 2013 6:21 am Omeros Obtains Regulatory Approval to Initiate Phase 1 Clinical Trial for Lead Antibody in MASP-2 Program - Jun 13th, 2013 5:00 am 4 Healthcare Stock Stories To Close Out the Week - May 31st, 2013 4:25 pm Omeros Reports Positive Results from OMS824 Positron Emission Tomography Clinical Trial - May 31st, 2013 5:00 am Omeros Files CTA for aHUS Candidate - May 29th, 2013 4:30 pm OMEROS CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders - May 29th, 2013 8:21 am FDA Accepts Omeros' IND for OMS824 - May 28th, 2013 4:59 pm Omeros Files Clinical Trial Application for Lead Antibody in MASP-2 Program - May 28th, 2013 5:00 am Omeros prepares for two studies of OMS824 - May 23rd, 2013 12:21 pm Omeros prepares for two studies of OMS824 - May 23rd, 2013 12:21 pm Omeros announces investigational NDA cleared by FDA for OMS824 - May 23rd, 2013 5:03 am Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease - May 23rd, 2013 5:00 am Omeros to Present at Two Upcoming Conferences - May 22nd, 2013 5:00 am OMEROS CORP Financials - May 17th, 2013 11:04 am Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock - May 14th, 2013 10:45 am Investors are Digesting These Healthcare Stock Earnings Insights - May 12th, 2013 9:55 am Short Interest Jumps 41.2% For OMER - May 10th, 2013 1:32 pm OMEROS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and Ex - May 10th, 2013 8:27 am Omeros Corporation Reports First Quarter 2013 Financial Results - May 10th, 2013 5:00 am View All Current Headlines >>